With one foot already in oncology, biosimilars player Coherus is looking to make a splash in ophthalmology with ambitions to launch rivals to Lucentis and Eylea, as well as Avastin, in the US in the coming years. The US-based firm has acknowledged the competition it faces for biosimilars to Lucentis as Bausch Health picked up rights to Stada and Xbrane’s candidate earlier this month.
Bausch Health’s agreement for the US rights to Xbrane and Stada’s biosimilar Lucentis (ranibizumab) candidate doesn’t change Coherus BioSciences’ aspirations or projections for the overall US biosimilar ophthalmology market, company head Denny Lanfear says.
Earlier this month, Bausch, formerly Valeant Pharmaceuticals, took the US rights to Xbrane’s Xlucane candidate, agreeing to an upfront and...
An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.
After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.
Laboratorio Elea has struck a deal with Nichi-Iko Pharmaceutical to market the Japanese firm’s infliximab biosimilar in Argentina.
